Top-News
Pharmazeutika USA

Poseida Therapeutics News

Aktie
WKN:  A2PEYK ISIN:  US73730P1084 US-Symbol:  PSTX
2,574 €
-0,602 €
-18,95%
08.05.24 19:29:05
Handeln Depot/Watchlist
Aktienanzahl *
95,62 Mio.
Marktkapitalisierung *
303,96 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 26.12.2023

Poseida Therapeutics News

14.05.24 - PR Newswire
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 PR Newswire
09.05.24 - PR Newswire
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting PR Newswire
01.05.24 - PR Newswire
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology PR Newswire
01.05.24 - PR Newswire
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology PR Newswire
18.04.24 - PR Newswire
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting PR Newswire
17.04.24 - PR Newswire
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus PR Newswire
08.04.24 - PR Newswire
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple ...
01.04.24 - PR Newswire
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
25.03.24 - PR Newswire
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer PR Newswire
19.03.24 - PR Newswire
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference PR Newswire
13.03.24 - PR Newswire
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma PR Newswire
07.03.24 - PR Newswire
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 PR Newswire
04.03.24 - PR Newswire
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
04.01.24 - PR Newswire
Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones
Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones PR Newswire
10.12.23 - PR Newswire
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-​Refractory Multiple Myeloma at the 65th American ...
09.11.23 - PR Newswire
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023 PR Newswire
07.11.23 - PR Newswire
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
Poseida Therapeutics to Present at Two Upcoming Investor Conferences PR Newswire
02.11.23 - PR Newswire
Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition
Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition PR Newswire
09.10.23 - PR Newswire
Poseida Therapeutics Announces Leadership Transition
Poseida Therapeutics Announces Leadership Transition PR Newswire
05.09.23 - PR Newswire
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
Poseida Therapeutics to Present at Two Upcoming Investor Conferences PR Newswire

Newssuche

Videos

newspaper
14.05.24 -12,37%
Technical Trading: DAX dienstags Long
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »